Boston Scientific Corporation
BSX · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $145 | $159 | $149 | $132 |
| - Cash | $0 | $1 | $1 | $0 |
| + Debt | $0 | $12 | $12 | $11 |
| Enterprise Value | $145 | $170 | $160 | $142 |
| Revenue | $5 | $5 | $5 | $5 |
| % Growth | 0.1% | 8.5% | 2.2% | – |
| Gross Profit | $4 | $3 | $3 | $3 |
| % Margin | 69.9% | 67.7% | 63.3% | 58.6% |
| EBITDA | $1 | $1 | $1 | $1 |
| % Margin | 20.3% | 27% | 26.1% | 23.5% |
| Net Income | $1 | $1 | $1 | $1 |
| % Margin | 14.9% | 15.7% | 14.5% | 12.4% |
| EPS Diluted | 0.5 | 0.53 | 0.451 | 0.38 |
| % Growth | -5.7% | 17.4% | 18.9% | – |
| Operating Cash Flow | – | $1 | $1 | $1 |
| Capital Expenditures | – | -$0 | -$0 | -$0 |
| Free Cash Flow | – | $1 | $0 | $1 |